Diabetes Treatment Report

www.DiabetesTreatmentReport.com

admin

Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00338-4

Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device
A.M. James Shapiro
David Thompson
Thomas W. Donner
Evert J. Kroon
Kevin A. D’Amour
Howard L. Foyt 9
Show all authors
Show footnotes
Open AccessPublished:December 02, 2021DOI:https://doi.org/10.1016/j.xcrm.2021.100466

Initial data suggest that pluripotent stem cells, which can be propagated to the desired biomass and differentiated into pancreatic islet-like tissue, may offer a scalable, renewable alternative to pancreatic islet transplants.

Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked: “A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.”

https://www.nytimes.com/2021/11/27/health/diabetes-cure-stem-cells.html

Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.
A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Brian Shelton may be the first person cured of Type 1 diabetes. “It’s a whole new life,” Mr. Shelton said. “It’s like a miracle.”Credit…Amber Ford for The New York Times
Gina Kolata
By Gina Kolata
Nov. 27, 2021

Mr. Shelton’s treatment, known as an early phase safety trial, called for careful follow-up and required starting with half the dose that would be used later in the trial, noted Dr. James Markmann, Mr. Shelton’s surgeon at Mass General who is working with Vertex on the trial. No one expected the cells to function so well, he said.

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes

https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-day-90-data-first-patient-phase-12

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes

Device-Less Technique in Islet Transplantation

https://clinicaltrials.gov/ct2/show/NCT05073302?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=09%2F27%2F2021&lupd_d=14&sort=nwst

STUDY TITLE:
Device-Less Technique in Islet Transplantation

DESCRIPTION:
Condition:   Type 1 Diabetes
Intervention:   Procedure: Implantation of Nylon catheter (Device-less sentinel unit)
Sponsors:   University of Alberta;   Juvenile Diabetes Research Foundation
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT05073302

FIRST POSTED:
Mon, 11 Oct 2021 12:00:00 EDT

LAST UPDATE POSTED:
10/11/21 07:14AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT05073302?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=09%2F27%2F2021&lupd_d=14&sort=nwst

Back to top